Posted by Michael Wonder on 04 Oct 2022
Cue Biopharma granted FDA fast track designation for CUE-101 for the treatment of recurrent/metastatic head and neck squamous cell carcinoma
4 October 2022 - Cue Biopharma announced today that the U.S. FDA has granted fast track designation to CUE-101, its lead clinical drug candidate from the CUE-100 series of interleukin 2 based biologics, for the treatment of patients with human papilloma virus recurrent/metastatic head and neck squamous cell carcinoma as a monotherapy and in combination with pembrolizumab.
CUE-101 is Cue Biopharma’s lead clinical drug candidate from the CUE-100 series of interleukin 2 based biologics.
